PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.77%
Negative revenue growth while 3088.T stands at 1.28%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.75%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-31.49%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-35.54%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-32.23%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-32.22%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-32.22%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
58.88%
10Y revenue/share CAGR above 1.5x 3088.T's 35.51%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-14.93%
Negative 5Y CAGR while 3088.T stands at 19.62%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
36.94%
3Y revenue/share CAGR above 1.5x 3088.T's 13.32%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
127.10%
Net income/share CAGR at 50-75% of 3088.T's 205.08%. Martin Whitman might question if the firm’s product or cost base lags behind.
-26.01%
Negative 5Y net income/share CAGR while 3088.T is 77.87%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
18.92%
Below 50% of 3088.T's 89.94%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
175.31%
Equity/share CAGR of 175.31% while 3088.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
21.78%
Below 50% of 3088.T's 64.40%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
68.66%
3Y equity/share CAGR above 1.5x 3088.T's 29.22%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Below 50% of 3088.T's 150.00%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
-18.18%
Negative near-term dividend growth while 3088.T invests at 66.67%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
8.70%
AR growth well above 3088.T's 3.44%. Michael Burry fears inflated revenue or higher default risk in the near future.
9.23%
Inventory growth well above 3088.T's 0.25%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.72%
Asset growth well under 50% of 3088.T's 3.55%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.25%
1.25-1.5x 3088.T's 2.55%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-7.42%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
1.66%
SG&A growth well above 3088.T's 1.84%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.